Cargando…

Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review

The aim of this retrospective chart review study was to examine the cost effectiveness of angiotensin-converting enzyme inhibitors (ACEIs); angiotensin receptor blockers (ARBs); and dihydropyridine calcium channel blockers (CCBs) such as amlodipine, monotherapies in the management of essential hyper...

Descripción completa

Detalles Bibliográficos
Autores principales: AlRuthia, Yazed, Alotaibi, Fahad, Jamal, Amr, Sales, Ibrahim, Alwhaibi, Monira, Alqahtani, Nawaf, AlNajrany, Sina M., Almalki, Khalid, Alsaigh, Abdulaziz, Mansy, Wael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304800/
https://www.ncbi.nlm.nih.gov/pubmed/34202109
http://dx.doi.org/10.3390/healthcare9070798
_version_ 1783727422040965120
author AlRuthia, Yazed
Alotaibi, Fahad
Jamal, Amr
Sales, Ibrahim
Alwhaibi, Monira
Alqahtani, Nawaf
AlNajrany, Sina M.
Almalki, Khalid
Alsaigh, Abdulaziz
Mansy, Wael
author_facet AlRuthia, Yazed
Alotaibi, Fahad
Jamal, Amr
Sales, Ibrahim
Alwhaibi, Monira
Alqahtani, Nawaf
AlNajrany, Sina M.
Almalki, Khalid
Alsaigh, Abdulaziz
Mansy, Wael
author_sort AlRuthia, Yazed
collection PubMed
description The aim of this retrospective chart review study was to examine the cost effectiveness of angiotensin-converting enzyme inhibitors (ACEIs); angiotensin receptor blockers (ARBs); and dihydropyridine calcium channel blockers (CCBs) such as amlodipine, monotherapies in the management of essential hypertension among adult patients (≥18 years) without cancer, cardiovascular disease, and chronic kidney disease in the primary care clinics of a university-affiliated tertiary care hospital. Patients were followed up for at least 12 months from the initiation of therapy. Propensity score bin bootstrapping with 10,000 replications was conducted to generate the 95% confidence intervals (CI) for both treatment outcome (e.g., reduction of the systolic (SBP) and diastolic blood pressures (DBP) in mmHG) and the cost (e.g., costs of drugs, clinic visits, and labs in Saudi riyals (SAR)). Among the 153 included patients who met the inclusion criteria, 111 patients were on ACEIs/ARBs, while 44 patients were on amlodipine. On the basis of the bootstrap distribution, we found that the use of ACEIs/ARBs was associated with an incremental reduction of SBP of up to 4.46 mmHg but with an incremental cost of up to SAR 116.39 (USD 31.04), which results in an incremental cost effectiveness ratio (ICER) of SAR 26.09 (USD 6.95) per 1 mmHg reduction with 55.26% level of confidence. With regard to DBP, ACEIs/ARBs were associated with an incremental reduction of DBP of up to 5.35 mmHg and an incremental cost of up to SAR 144.96 (USD 38.66), which results in an ICER of SAR 27.09 (USD 7.23) per 1 mmHg reduction with 68.10% level of confidence. However, ACEIs/ARBs were less effective and costlier than amlodipine in reducing SBP and DBP with 44.74% and 31.89% levels of confidence, respectively. The findings of this study indicate that the use of ACEI or ARB as a monotherapy seems to be more effective than amlodipine monotherapy in the management of essential hypertension in primary care settings with minimal incremental cost.
format Online
Article
Text
id pubmed-8304800
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83048002021-07-25 Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review AlRuthia, Yazed Alotaibi, Fahad Jamal, Amr Sales, Ibrahim Alwhaibi, Monira Alqahtani, Nawaf AlNajrany, Sina M. Almalki, Khalid Alsaigh, Abdulaziz Mansy, Wael Healthcare (Basel) Article The aim of this retrospective chart review study was to examine the cost effectiveness of angiotensin-converting enzyme inhibitors (ACEIs); angiotensin receptor blockers (ARBs); and dihydropyridine calcium channel blockers (CCBs) such as amlodipine, monotherapies in the management of essential hypertension among adult patients (≥18 years) without cancer, cardiovascular disease, and chronic kidney disease in the primary care clinics of a university-affiliated tertiary care hospital. Patients were followed up for at least 12 months from the initiation of therapy. Propensity score bin bootstrapping with 10,000 replications was conducted to generate the 95% confidence intervals (CI) for both treatment outcome (e.g., reduction of the systolic (SBP) and diastolic blood pressures (DBP) in mmHG) and the cost (e.g., costs of drugs, clinic visits, and labs in Saudi riyals (SAR)). Among the 153 included patients who met the inclusion criteria, 111 patients were on ACEIs/ARBs, while 44 patients were on amlodipine. On the basis of the bootstrap distribution, we found that the use of ACEIs/ARBs was associated with an incremental reduction of SBP of up to 4.46 mmHg but with an incremental cost of up to SAR 116.39 (USD 31.04), which results in an incremental cost effectiveness ratio (ICER) of SAR 26.09 (USD 6.95) per 1 mmHg reduction with 55.26% level of confidence. With regard to DBP, ACEIs/ARBs were associated with an incremental reduction of DBP of up to 5.35 mmHg and an incremental cost of up to SAR 144.96 (USD 38.66), which results in an ICER of SAR 27.09 (USD 7.23) per 1 mmHg reduction with 68.10% level of confidence. However, ACEIs/ARBs were less effective and costlier than amlodipine in reducing SBP and DBP with 44.74% and 31.89% levels of confidence, respectively. The findings of this study indicate that the use of ACEI or ARB as a monotherapy seems to be more effective than amlodipine monotherapy in the management of essential hypertension in primary care settings with minimal incremental cost. MDPI 2021-06-25 /pmc/articles/PMC8304800/ /pubmed/34202109 http://dx.doi.org/10.3390/healthcare9070798 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
AlRuthia, Yazed
Alotaibi, Fahad
Jamal, Amr
Sales, Ibrahim
Alwhaibi, Monira
Alqahtani, Nawaf
AlNajrany, Sina M.
Almalki, Khalid
Alsaigh, Abdulaziz
Mansy, Wael
Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review
title Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review
title_full Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review
title_fullStr Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review
title_full_unstemmed Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review
title_short Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review
title_sort cost effectiveness of aceis/arbs versus amlodipine monotherapies: a single-center retrospective chart review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304800/
https://www.ncbi.nlm.nih.gov/pubmed/34202109
http://dx.doi.org/10.3390/healthcare9070798
work_keys_str_mv AT alruthiayazed costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT alotaibifahad costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT jamalamr costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT salesibrahim costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT alwhaibimonira costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT alqahtaninawaf costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT alnajranysinam costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT almalkikhalid costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT alsaighabdulaziz costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview
AT mansywael costeffectivenessofaceisarbsversusamlodipinemonotherapiesasinglecenterretrospectivechartreview